Abstract
Naturally occurring mutations in HIV–1–infected patients have important implications for therapy and the outcome of clinical studies. However, little is known about the prevalence of mutations that confer resistance to HIV–1 protease inhibitors in isolates derived from patients naive for such inhibitors. In the first clinical application of high–density oligonucleotide arraysequencing, the sequences of 167 viral isolates from 102 patients have been determined. The DNA sequence of USA HIV–1 clade B proteases was found to be extremely variable and 47.% of the 99 amino acid positions varied. This level of amino acid diversity is greater than that previously known for all worldwide HIV–1 clades combined (40%). Many of the amino acid changes that are known to contribute to drug resistance occurred as natural polymorphisms in isolates from patients who had never received protease inhibitors.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Kohl, N.E. et al. Active human immunodeficiency virus protease is required for viral infectivity. Proc. Natl. Acad. Sci. USA 85, 4686–4690 (1988).
LeGrice, S.F., Mills, J. & Mous, J. Active site mutations of AIDS virus protease and its alleviation by trans complementation. EMBO. J. 7 2547–2553 (1988).
Peng, C., Ho, B.K., Chang, T.W. & Chang, N.T. Role of human immunodeficiency virus type 1-specific protease in core protein maturation and viral infectivity. J. Virol. 63, 2550–2556 (1989).
Meyers, G. et al. (eds.) Human Retroviruses and AIDS, Vol. I, 79–83; vol. III, 97–106(Los Alamos National Laboratory, New Mexico, 1994).
Miller, M., Jaskólski, M., Mohana Rao, J.K., Leis, J. & Wlodawer, A. Crystal structure of a retroviral protease proves relationship to aspartic protease family. Nature 337, 576–578 (1989).
Toh, H., Ono, M., Saigo, K. & Miyata, T. Retroviral protease-like sequence in yeast transposon Ty1 . Nature 315, 691 (1985).
Pillay, D., Bryant, M., Getman, D. & Richman, D.D. HIV-1 protease inhibitors: Their development, mechanism of action and clinical potential. Rev. Med. Virol. 5, 23–33 (1995).
Mellors, J.W., Larder, B.A. & Schinazi, R.F. Mutations in HIV-1 reverse transcriptase and protease associated with drug resistance. Int. Antiviral News 3, 8–13 (1995).
Condra, J.H. et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374, 569–571 (1995).
Fodor, S.P. et al. Light-directed, spatially addressable parallel chemical synthesis. Science 251, 767–773 (1991).
Pease, A.C. et al. Light-generated oligonucleotide arrays for rapid DNA sequence analysis. Proc. Natl. Acad. Sci. USA 91, 5022–5026 (1994).
Lipshutz, R.J. Using oligonucleotide probe arrays to access genetic diversity. Biotechniques 19, 442–447 (1995).
Lipshutz, R.J. & Fodor, S.P.A. Advanced DNA sequencing technologies. Curr. Opin. Struct. Biol. 4, 376–380 (1994).
Rose, B. et al. in HIV Drug-Resistance Third International Workshop, p. 17, 2–5 August 1994, Kauai, Hawaii (1994).
Kaplan, A.H. et al. Selection of multiple human immunodeficiency virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral protease. Proc. Natl. Acad. Sci. USA 91, 5022–5026 (1994).
Tisdale, M. in HIV Drug-Resistance Third International Workshop, p. 14, 2–5 August 1994, Kauai, Hawaii (1994).
Sanchez-Pescador, R. et al. Nucleotide sequence and expression of an AIDS-associated retrovirus (ARV-2). Science 227, 484–492 (1985).
Theodore, T. & Buckler-White, A. in Human Retroviruses and AIDS (eds. Myers, G. et al.) 162–165 (Los Alamos National Laboratory, New Mexico, (1990).
Ratner, L. et al. Complete nucleotide sequence of the AIDS virus, HTL-VIII. Nature 313, 277–284 (1985).
Gingeras, T.R. et al. Use of self-sustained sequence replication (3SR) amplification reaction to analyze and detect mutations in zidovudine-resistant human immunodeficiency virus. J. Infect. Dis. 164, 1066–1074 (1991).
Delwart, E.L. et al. Genetic relationships determined by a DNA heteroduplex mobility assay: Analysis of HIV-1 env genes. Science 262, 1257–1261 (1993).
Coffin, J.M. HIV population dynamics in vivo: Implications for genetic variation, pathogenesis, and therapy. Science 267, 483–489 (1995).
Ho, D.D. et al. Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor. J. Virol. 68, 2016–2020 (1994).
Eckert, K.A. & Kunkel, T.A. DNA polymerase fidelity and the polymerase chain reaction. PCR Methods Appl. 1, 17–24 (1991).
Tabor, S. & Richardson, C.C. A single hydroxyl moiety in a pol I-type DNA polymerase is responsible for distinguishing between deoxy-and dideoxynucleotides. Proc. Natl. Acad. Sci. USA 92, 6639–6643 (1995).
Potts, K.E. et al. in HIV Drug-Resistance Third International Workshop, p. 4, 2–5 August 1994, Kauai, Hawaii (1994).
Jacobsen, H. et al. in HIV Drug-Resistance Third International Workshop, p. 16, 2–5 August 1994, Kauai, Hawaii (1994).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kozal, M., Shah, N., Shen, N. et al. Extensive polymorphisms observed in HIV–1 clade B protease gene using high–density oligonucleotide arrays. Nat Med 2, 753–759 (1996). https://doi.org/10.1038/nm0796-753
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm0796-753
- Springer Nature America, Inc.
This article is cited by
-
Treatment-associated polymorphisms in protease are significantly associated with higher viral load and lower CD4 count in newly diagnosed drug-naive HIV-1 infected patients
Retrovirology (2012)
-
Functional genomics as a tool in virus research
Indian Journal of Microbiology (2008)
-
Microarray-based identification of antigenic variants of foot-and-mouth disease virus: a bioinformatics quality assessment
BMC Genomics (2006)